Insights from 2023 ESMO Annual Meeting


 

ESMO 2023 Insights: "RAMOSE Trial - Osimertinib+/-Ramucirumab in TKI-Naïve EGFRm mNSCLC"

229 views
November 8, 2023
Comments 0
Login to view comments. Click here to Login